A North American, Prospective, Multicenter Assessment of the Mitroflow Aortic Pericardial Prosthesis

John Conte, Neil Weissman, Joseph A. Dearani, Joseph Bavaria, David Heimansohn, Walter Dembitsky, Daniel Doyle

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: The aim of the Mitroflow aortic pericardial valve study was to prospectively assess performance of the Mitroflow prosthesis among North American patients. Methods: The study was conducted between November 2003 and December 2007 on patients requiring aortic valve replacement. The study cohort consisted of 689 patients (391 male, 298 female), with a mean age of 74.3 ± 8.4 years, and 46.6% of whom were New York Heart Association (NYHA) class I/II preoperatively. Patients were followed at 3 to 6 months and yearly until study closure. Mean follow-up was 25.7 ± 12 months, and total follow-up was 1,474.4 patient-years, with a maximum of 48.7 months. Results: Postoperatively, more than 97% of evaluated patients were NYHA class I/II. At 3 years, 131 patients had died, for an actuarial survival of 79.1%; and the 3-year actuarial freedom from valve-related death, valve explant, all valve reoperation, and structural valve dysfunction was 97.0%, 98.1%, 97.9%, and 99.2%, respectively. Other valve-related complications included prosthetic valve endocarditis (1.4% per patient-year), thromboembolic episodes (1.3% per patient-year), major embolism (0.5% per patient-year), perivalvular leak (0.6% per patient-year), and major anticoagulation-related bleeding (0.6% per patient-year). Echocardiograms at 1 year showed mean pressure gradients averaged from 7.3 ± 1.8 mm Hg to 13.4 ± 5.1 mm Hg, and peak gradients averaged from 14.3 ± 4.7 mm Hg to 26.0 ± 9.2 mm Hg for valve sizes 27 to 19. Aortic regurgitation in patients was absent/trace (90.2%) or mild (8.7%); none was severe. Conclusions: The early results of this study show a low incidence of valve-related adverse events and excellent hemodynamic performance. Continued follow-up is needed to determine if long-term durability in North American patients is comparable to that in previous reports on the durability of the Mitroflow valve.

Original languageEnglish (US)
JournalAnnals of Thoracic Surgery
Volume90
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Prostheses and Implants
Aortic Valve
Aortic Valve Insufficiency
Endocarditis
Embolism
Reoperation
Cohort Studies
Hemodynamics
Hemorrhage
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Conte, J., Weissman, N., Dearani, J. A., Bavaria, J., Heimansohn, D., Dembitsky, W., & Doyle, D. (2010). A North American, Prospective, Multicenter Assessment of the Mitroflow Aortic Pericardial Prosthesis. Annals of Thoracic Surgery, 90(1). https://doi.org/10.1016/j.athoracsur.2010.02.108

A North American, Prospective, Multicenter Assessment of the Mitroflow Aortic Pericardial Prosthesis. / Conte, John; Weissman, Neil; Dearani, Joseph A.; Bavaria, Joseph; Heimansohn, David; Dembitsky, Walter; Doyle, Daniel.

In: Annals of Thoracic Surgery, Vol. 90, No. 1, 07.2010.

Research output: Contribution to journalArticle

Conte, John ; Weissman, Neil ; Dearani, Joseph A. ; Bavaria, Joseph ; Heimansohn, David ; Dembitsky, Walter ; Doyle, Daniel. / A North American, Prospective, Multicenter Assessment of the Mitroflow Aortic Pericardial Prosthesis. In: Annals of Thoracic Surgery. 2010 ; Vol. 90, No. 1.
@article{865453166ccd4737a508e08279edd727,
title = "A North American, Prospective, Multicenter Assessment of the Mitroflow Aortic Pericardial Prosthesis",
abstract = "Background: The aim of the Mitroflow aortic pericardial valve study was to prospectively assess performance of the Mitroflow prosthesis among North American patients. Methods: The study was conducted between November 2003 and December 2007 on patients requiring aortic valve replacement. The study cohort consisted of 689 patients (391 male, 298 female), with a mean age of 74.3 ± 8.4 years, and 46.6{\%} of whom were New York Heart Association (NYHA) class I/II preoperatively. Patients were followed at 3 to 6 months and yearly until study closure. Mean follow-up was 25.7 ± 12 months, and total follow-up was 1,474.4 patient-years, with a maximum of 48.7 months. Results: Postoperatively, more than 97{\%} of evaluated patients were NYHA class I/II. At 3 years, 131 patients had died, for an actuarial survival of 79.1{\%}; and the 3-year actuarial freedom from valve-related death, valve explant, all valve reoperation, and structural valve dysfunction was 97.0{\%}, 98.1{\%}, 97.9{\%}, and 99.2{\%}, respectively. Other valve-related complications included prosthetic valve endocarditis (1.4{\%} per patient-year), thromboembolic episodes (1.3{\%} per patient-year), major embolism (0.5{\%} per patient-year), perivalvular leak (0.6{\%} per patient-year), and major anticoagulation-related bleeding (0.6{\%} per patient-year). Echocardiograms at 1 year showed mean pressure gradients averaged from 7.3 ± 1.8 mm Hg to 13.4 ± 5.1 mm Hg, and peak gradients averaged from 14.3 ± 4.7 mm Hg to 26.0 ± 9.2 mm Hg for valve sizes 27 to 19. Aortic regurgitation in patients was absent/trace (90.2{\%}) or mild (8.7{\%}); none was severe. Conclusions: The early results of this study show a low incidence of valve-related adverse events and excellent hemodynamic performance. Continued follow-up is needed to determine if long-term durability in North American patients is comparable to that in previous reports on the durability of the Mitroflow valve.",
author = "John Conte and Neil Weissman and Dearani, {Joseph A.} and Joseph Bavaria and David Heimansohn and Walter Dembitsky and Daniel Doyle",
year = "2010",
month = "7",
doi = "10.1016/j.athoracsur.2010.02.108",
language = "English (US)",
volume = "90",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - A North American, Prospective, Multicenter Assessment of the Mitroflow Aortic Pericardial Prosthesis

AU - Conte, John

AU - Weissman, Neil

AU - Dearani, Joseph A.

AU - Bavaria, Joseph

AU - Heimansohn, David

AU - Dembitsky, Walter

AU - Doyle, Daniel

PY - 2010/7

Y1 - 2010/7

N2 - Background: The aim of the Mitroflow aortic pericardial valve study was to prospectively assess performance of the Mitroflow prosthesis among North American patients. Methods: The study was conducted between November 2003 and December 2007 on patients requiring aortic valve replacement. The study cohort consisted of 689 patients (391 male, 298 female), with a mean age of 74.3 ± 8.4 years, and 46.6% of whom were New York Heart Association (NYHA) class I/II preoperatively. Patients were followed at 3 to 6 months and yearly until study closure. Mean follow-up was 25.7 ± 12 months, and total follow-up was 1,474.4 patient-years, with a maximum of 48.7 months. Results: Postoperatively, more than 97% of evaluated patients were NYHA class I/II. At 3 years, 131 patients had died, for an actuarial survival of 79.1%; and the 3-year actuarial freedom from valve-related death, valve explant, all valve reoperation, and structural valve dysfunction was 97.0%, 98.1%, 97.9%, and 99.2%, respectively. Other valve-related complications included prosthetic valve endocarditis (1.4% per patient-year), thromboembolic episodes (1.3% per patient-year), major embolism (0.5% per patient-year), perivalvular leak (0.6% per patient-year), and major anticoagulation-related bleeding (0.6% per patient-year). Echocardiograms at 1 year showed mean pressure gradients averaged from 7.3 ± 1.8 mm Hg to 13.4 ± 5.1 mm Hg, and peak gradients averaged from 14.3 ± 4.7 mm Hg to 26.0 ± 9.2 mm Hg for valve sizes 27 to 19. Aortic regurgitation in patients was absent/trace (90.2%) or mild (8.7%); none was severe. Conclusions: The early results of this study show a low incidence of valve-related adverse events and excellent hemodynamic performance. Continued follow-up is needed to determine if long-term durability in North American patients is comparable to that in previous reports on the durability of the Mitroflow valve.

AB - Background: The aim of the Mitroflow aortic pericardial valve study was to prospectively assess performance of the Mitroflow prosthesis among North American patients. Methods: The study was conducted between November 2003 and December 2007 on patients requiring aortic valve replacement. The study cohort consisted of 689 patients (391 male, 298 female), with a mean age of 74.3 ± 8.4 years, and 46.6% of whom were New York Heart Association (NYHA) class I/II preoperatively. Patients were followed at 3 to 6 months and yearly until study closure. Mean follow-up was 25.7 ± 12 months, and total follow-up was 1,474.4 patient-years, with a maximum of 48.7 months. Results: Postoperatively, more than 97% of evaluated patients were NYHA class I/II. At 3 years, 131 patients had died, for an actuarial survival of 79.1%; and the 3-year actuarial freedom from valve-related death, valve explant, all valve reoperation, and structural valve dysfunction was 97.0%, 98.1%, 97.9%, and 99.2%, respectively. Other valve-related complications included prosthetic valve endocarditis (1.4% per patient-year), thromboembolic episodes (1.3% per patient-year), major embolism (0.5% per patient-year), perivalvular leak (0.6% per patient-year), and major anticoagulation-related bleeding (0.6% per patient-year). Echocardiograms at 1 year showed mean pressure gradients averaged from 7.3 ± 1.8 mm Hg to 13.4 ± 5.1 mm Hg, and peak gradients averaged from 14.3 ± 4.7 mm Hg to 26.0 ± 9.2 mm Hg for valve sizes 27 to 19. Aortic regurgitation in patients was absent/trace (90.2%) or mild (8.7%); none was severe. Conclusions: The early results of this study show a low incidence of valve-related adverse events and excellent hemodynamic performance. Continued follow-up is needed to determine if long-term durability in North American patients is comparable to that in previous reports on the durability of the Mitroflow valve.

UR - http://www.scopus.com/inward/record.url?scp=77953655844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953655844&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2010.02.108

DO - 10.1016/j.athoracsur.2010.02.108

M3 - Article

C2 - 20609765

AN - SCOPUS:77953655844

VL - 90

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -